Restless legs syndrome: Nonpharmacologic and pharmacologic treatments

Geriatrics

Volumn 62, Issue 10, 2007, Pages 13-16

  Winkelman, John W ^a   Allen, Richard P ^a   Tenzer, Penny ^a   Hening, Wayne ^a  

^a NONE

Author keywords

Anticonvulsants; Dopamine agonists; Iron supplementation; Opioids; Restless legs syndrome; Sedatives; Sleep deprivation

Indexed keywords

ALCOHOL; AMFEBUTAMONE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CARBIDOPA PLUS LEVODOPA; CLONAZEPAM; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; FERRITIN; GABAPENTIN; IRON; LEVODOPA; METHADONE; NEUROLEPTIC AGENT; OPIATE DERIVATIVE; OXYCODONE; PERCOCET; PRAMIPEXOLE; ROPINIROLE; TEMAZEPAM; TRAMADOL; TRANSFERRIN; TRIAZOLAM; ZOLPIDEM; ZOLPIDEM TARTRATE;

COGNITIVE DEFECT; CONSTIPATION; DISEASE SEVERITY; DIZZINESS; DRUG DOSE TITRATION; DRUG INDICATION; FATIGUE; HEADACHE; HUMAN; INSOMNIA; IRON DEFICIENCY; NAUSEA; OPIATE ADDICTION; ORTHOSTATIC HYPOTENSION; PERIPHERAL EDEMA; RESTLESS LEGS SYNDROME; REVIEW; SEDATION; SIDE EFFECT; SLEEP; SOMNOLENCE; SYMPTOM;

AMINES; ANEMIA, IRON-DEFICIENCY; ANTICONVULSANTS; BENZOTHIAZOLES; CLONAZEPAM; CYCLOHEXANECARBOXYLIC ACIDS; DOPAMINE AGENTS; DOPAMINE AGONISTS; FERRITINS; GAMMA-AMINOBUTYRIC ACID; HUMANS; INDOLES; IRON; LEVODOPA; RESTLESS LEGS SYNDROME; TRACE ELEMENTS;

EID: 35349029765     PISSN: 0016867X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Earley CJ. Clinical practice: restless legs syndrome. N Engl J Med. 2003;348(21):2103-2109.
2. Silber MH, Ehrenberg BL, Allen RP, et al. An algorithm for the management of restless legs syndrome. Mayo Clin Proc. 2004; 79(7):916-922 .
3. O'Keeffe ST, Gavin K, Lavan JN. Iron status and restless legs syndrome in the elderly. Age Ageing. 1994;23(3):200-203.
4. Trenkwalder C, Collado-Seidel V, Kazenwadel J, et al. One-year treatment with standard and sustained-release levodopa: appropriate long-term treatment of restless legs syndrome? Mov Disord. 2003;18(10):1184-1189.
5. Earley CJ, Heckler D, Allen RP. The treatment of restless legs syndrome with intravenous iron dextran. Sleep Med. 2004;5(3):231-235.
6. Becker PM, Jamieson AO, Brown WD. Dopaminergic agents in restless legs syndrome and periodic limb movements of sleep: response and complications of extended treatment in 49 cases. Sleep. 1993; 16(8):713-716.
7. Benes H, Kurella B, Kummer J, et al. Rapid onset of action of levodopa in restless legs syndrome: a double-blind, randomized, multicenter, crossover trial. Sleep. 1999;22(8): 1073-1081.
8. Collado-Seidel V, Kazenwadel J, Wetter TC, et al. A controlled study of additional sr-L-dopa in L-dopa-responsive restless legs syndrome with late-night symptoms. Neurology. 1999; 52(2):285-290.
9. Stiasny-Kolster K, Kohnen R, Moller JC, et al. Validation of the "L-DOPA test" for diagnosis of restless legs syndrome. Mov Disord. 2006;21(9):1333-1339.
10. Trenkwalder C, Garcia-Borreguero D, Montagna P, et al. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry. 2004;75(1):92-97.
11. Walters AS, Ondo WG, Dreykluft T, et al. Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov Disord. 2004;19(12):1414-1423.
12. Bogan RK, Fry JM, Schmidt MH, et al. Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc. 2006;81(1):17-27.
13. Pellecchia MT, Vitale C, Sabatini M, et al. Ropinirole as a treatment of restless legs syndrome in patients on chronic hemodialysis: an open randomized crossover trial versus levodopa sustained release. Clin Neuropharmacol. 2004;27(4):178-181.
14. Partinen M, Hirvonen K, Jama L, et al. Efficacy and safety of pramipexole in idiopathic restless legs syndrome: a polysomnographic dose-finding study. The PRELUDE study. Sleep Med. 2006;7(5):407-417.
15. Trenkwalder C, Stiasny-Kolster K, Kupsch A, et al. Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome. Mov Disord. 2006;21(9):1404-1410.
16. Winkelman JW, Sethi KD, Kushida CA, et al. Pramipexole is safe and effective after 12 weeks of treatment in restless legs syndrome. Neurology. 2006;67(6):1034-1039.
17. Silber MH. Calming restless legs. Sleep. 2004;27(5):839-841.
18. Winkelman JW, Johnston L. Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). Sleep Med. 2004;5(1):9-14.
19. Ondo WG. Methadone for refractory restless legs syndrome. Mov Disord. 2005;20(3): 345-348.
20. Earley CJ, Allen RP. Restless legs syndrome augmentation associated with tramadol. Sleep Medicine. 2006;7(7):592-593.
21. Walters AS, Winkelmann J, Trenkwalder C, et al. Long-term follow-up on restless legs syndrome patients treated with opioids. Mov Disord. 2001;16(6):1105-1109.
22. Garcia-Borreguero D, Larrosa O, de la Llave Y, et al. Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology. 2002;59(10):1573-1579.